IBIO iBio Inc Total Asset Value of Company
iBio, Inc. (IBIO) wields significant market influence through its RubrY AI system, which creates unique proteins to combat cancer and autoimmune pathologies. The business strategy relies on a balance between proprietary development and contract design of biologics. The price action of the securities reflects total assets at 61.14, while the digitalization of processes via AI has optimized laboratory supply through express channels.
Analytical breakdowns and data insights for company iBio Corp (IBIO)
- stock value and consensus price forecast:
- market capitalization data:
- issuer book value statistics:
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio iBio, Inc.|IBIO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio iBio Corporation|IBIO - Company Aggregate Debts|Debts to Book Capitalization iBio Corporation|IBIO - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings iBio|Interim Coverage Ratio ibioinc.com
- net income and valuation multiples indicators:
Fundamental valuation:iBio, Inc.
Investors are assessing the potential of iBio, Inc. (IBIO) through the ability of the RubrYc AI platform to generate value by developing high-precision antibodies. The dynamics of the company's total resources are based on a reverse ROA calculation, which allows for a real-time assessment of the market revaluation of the asset base between quarterly reports. High volatility in this metric signals capital instability, which is critical for risk assessment when scaling computing capacities.
Key competitors
Company Assets argenx.com (ARGX)|Aggregate Company Assets BioNTech|Abivax - Total Asset Value of Company|Company Total Assets ADMA|PTGX (Protagonist Corp) - Aggregate Asset Value|Company Total Assets IMVT (Immunovant, Inc.)|Company Total Assets kiniksa.com KNSA|GRFS - Aggregate Company Assets|Aggregate Asset Value ADPT (Adaptive Biotech)|Celldex (CLDX) - Aggregate Company Assets|Cumulative Company Assets Aurinia Corp|BCRX (BioCryst) - Company Total Assets|Company Total Assets veratx.com|Cumulative Company Assets DNTH (Dianthus Therapeutics, Inc.)|PHVS (Pharvaris NV) - Aggregate Asset Value|Company Total Assets ABCL (abcellera.com)|Company Total Asset Base Tourmaline (TRML)|PGEN - Aggregate Company Assets|pharming.com (PHAR) - Cumulative Company Assets|Nektar Therapeutics Inc. (NKTR) - Aggregate Company Assets|Cumulative Company Assets Upstream Bio, Inc.|Cumulative Company Assets ZBIO|Company Total Assets Immunome Bio|Aggregate Company Assets Gossamer Bio, Inc. (GOSS)|kalvista.com - Total Business Assets|Company Total Assets SEPN (Septerna)|Pieris Pharma (PVLA) - Company Assets|Savara Corp - Company Total Assets|Company Total Asset Base Rigel Corp RIGL|ANAB: Company Total Assets|ATXS (astriatx.com) - Aggregate Company Assets|ENGN (enGene) - Company Total Assets|RAPT Therapeutics Inc. (RAPT) - Company Total Asset Base|Aggregate Company Assets Aerovate Therapeutics Inc (JBIO)|ACRS - Company Assets|Kyverna Therapeutics - Cumulative Company Assets|Aggregate Asset Value TLSA|Cabaletta Bio - Company Total Assets|Company Total Asset Base Ventyx Biosciences Inc. VTYX|Theratechnologies Inc (THTX) - Aggregate Company Assets|Total Business Assets AVTX|ELDN (Eledon Pharmaceuticals) - Company Total Assets|Cumulative Company Assets agenusbio.com (AGEN)|Cumulative Company Assets CLYM (Climb Bio)|Company Total Asset Base Zura Bio Ltd|Company Total Assets ATYR (aTyr)|Company Total Asset Base Adagene Inc (ADAG)|Ikena Oncology, Inc. - Company Total Assets|STTK: Aggregate Company Assets|EQ: Company Total Assets|CNTB - Company Total Asset Base|Aggregate Company Assets Immunic Therapeutics|Company Assets Atara Biotherapeutics Inc ATRA|Aggregate Company Assets InflaRx N.V. (IFRX)|XFOR: Total Asset Value of Company|Company Total Assets ACET (Adicet Bio, Inc.)|Aggregate Asset Value CELU|INmune Bio Corp - Company Total Assets|BRNS - Company Total Assets|Kezar Life Sciences (KZR) - Aggregate Company Assets|sabbiotherapeutics.com - Aggregate Asset Value|Aggregate Company Assets Akari Therapeutics Plc|Cumulative Company Assets Enlivex Therapeutics, Ltd. (ENLV)|Company Total Assets QTTB|Company Total Assets GeoVax Corp (GOVX)|Edesa Biotech, Inc. - Cumulative Company Assets|Aggregate Asset Value CARM|XTL Biopharmaceuticals Ltd. - Company Total Assets|Company Total Asset Base Bolt Biotherapeutics BOLT|hcwbiologics.com (HCWB) - Aggregate Company Assets|Cumulative Company Assets Aptevo Therapeutics Inc.|Aggregate Company Assets AIM ImmunoTech Inc.|Cumulative Company Assets Aditxt Corp (ADTX)|Cumulative Company Assets GRI (GRI Bio)|Company Total Assets XORTX Therapeutics Inc (XRTX)|Aggregate Company Assets ReShape Lifesciences HIND|REVB: Total Business Assets|Indaptus Therapeutics - Company Total Assets|Company Assets scinai.com|CALI: Company Total Assets|AFMD - Company Total Asset Base|ALLK (Allakos Inc) - Company Total Assets|Aggregate Company Assets HOOK|Company Total Assets IGMS|Company Total Asset Base iteostherapeutics.com|Aggregate Company Assets Ocean Biomedical OCEA|TC BioPharm (Holdings) Plc (TCBP) - Company Assets|THRD: Cumulative Company Assets